Optimizing Management of Carcinoid Syndrome in Patients with Neuroendocrine Tumors
03/09/2018 - 03/08/2019
In support of improving care for neuroendocrine tumor patients with carcinoid syndrome, this Continuing Education (CE) activity has been planned and implemented by the Postgraduate Institute for Medicine and i3 Health. There is no fee to participate in or claim CE credit for this activity.
STATEMENT OF NEED
Carcinoid syndrome refers to a constellation of symptoms caused by the systemic release of humoral factors such as polypeptides, biogenic amines, and prostaglandins, mostly from well-differentiated neuroendocrine tumors. Patients frequently experience flushing, abdominal cramps, bronchospasms, hypotension, and diarrhea, which lead to impaired quality of life and daily functioning. In addition, complications such as carcinoid heart disease and mesenteric and/or retroperitoneal fibrosis increase the risk for morbidity and mortality. In general, patients affected by carcinoid syndrome have a higher tumor burden and lower survival rate compared with those who are not.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals involved in the management carcinoid syndrome in patients with neuroendocrine tumors.
Upon completion of this activity, participants should be able to:
- Anticipate the signs and symptoms of carcinoid syndrome in patients with neuroendocrine tumors
- Describe potentially life-threatening complications of carcinoid syndrome
- Apply supportive care strategies to provide symptom relief for patients with carcinoid syndrome
Pamela Ryan, RN, BSN
Neuroendocrine Tumor Program & Infusion Center, Ochsner Medical Center, Louisiana
Donna Williams, RN
Senior Research Nurse
Stanford Medicine, California